Doubts Linger Over Whether AVERROES Gives Any Advantage To Apixaban
Executive Summary
Bristol-Myers Squibb Co./Pfizer Inc. have evidence in hand that their investigational anticoagulant apixaban is useful in patients who can’t take warfarin. But any marketing gains for apixaban in this niche could be limited by physician skepticism about the patient population, assumptions that other similar drugs will be just as good in that population, and the recent FDA approval of the rival oral drug Pradaxa.
You may also be interested in...
Eliquis’ European Label Supports Superiority Claims
Bristol and Pfizer expect to launch novel anticoagulant Eliquis within weeks in Germany and the U.K. following approval in Europe on Nov. 20. Eliquis looks well-positioned to compete in Europe with a label reflecting superiority on safety, efficacy for stroke prevention and mortality.
Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected
Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.
Apixaban Impresses At ESC, Leading To Speculation About An Early Filing
Bristol and Pfizer put an early end to the Phase III study successfully comparing their anticoagulant to aspirin, and the preliminary data bode well for further results due out mid-2011, but will they wait?